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PRP1
INPATIENT AND OBSERVATION UNIT COSTS
FOR CHRONIC OBSTRUCTIVE PULMONARY
DISEASE (COPD)
O’Brien JA, Patrick AR, Duran P, Caro JJ
Caro Research Institute, Concord, MA, USA
OBJECTIVE: COPD is a common chronic adult respira-
tory problem in Europe and North America. Recently,
there has been an effort to prevent hospital admission by
treating and monitoring exacerbations in outpatient
Observation Units (OU). The objective of this study was
to estimate the costs of hospitalization and of OU stays
for COPD. METHODS: Data from the 1998 all age, 
all-payer Massachusetts hospital discharge and OU 
databases were analyzed. Cases were identiﬁed by princi-
pal ICD-9 diagnosis code and unique patient identiﬁer.
All accommodations, ancillaries and physician care were
included in cost estimates, which were adjusted for
medical inﬂation, cost-to-charge ratios, and reported in
2002US$. Massachusetts’ costs were adjusted to national
values. RESULTS: The analysis revealed 9,774 patients
admitted to hospital and 1,084 to OU. In the Hospital
Group, males = 41% and the mean age = 71 years. Age
and gender mix for patients in the OU group was similar.
The mean number of hospital admissions during year was
1.3 per patient (range: 1–14). The mean length of stay
was 5.4 days per admission; 8% of patients had a one-
day stay. The mean cost per hospitalization was $5,336,
$1,745 for a 1-day stay. The mean time spent in OU was
28 hours. Emergent status was assigned to 54% and
urgent status to 32% of OU patients. The mean cost per
OU stay was $1,559 and the mean annual number of OU
stays per COPD patient was 1.1 (range: 1–5). CON-
CLUSIONS: On average, OU stay costs are substantially
less than for an inpatient stay. When clinically appropri-
ate, a stay in the OU can provide a less costly alternative
for those who otherwise would require hospitalization,
even for just one day. The costs related to hospital and
OU stays for COPD provide two key pieces to under-
standing the economic burden of COPD.
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3329 STUDY TO EVALUATE HOSPITAL COSTS
FOR ACUTE EXACERBATION IN CHRONIC
OBSTRUCTIVE PULMONARY DISEASE IN SPAIN
(EPOC-COST STUDY)
García A1, Fernandez I2, Rejas J2, De-Miguel G3
1Carlos Haya Hospital, Malaga, Spain; 2Pﬁzer, S.A, Alcobendas,
Madrid, Spain; 3Boehringer Ingelheim, San Cugat del Valles,
Barcelona, Spain
OBJECTIVES: To evaluate the associated costs (from a
3rd payer perspective) due to the treatment of hospitalized
Chronic Obstructive Pulmonary Disease (COPD) exacer-
bation. METHODS: Retrospective review of 246 clinical
episodes of exacerbation in 4 tertiary hospitals (from
June-1999 to December-2001), a 5th hospital data are
under evaluation. The cost of the stay (hotel cost) used
was €228,12/day (DRG 88 of one of the participating
centers). The cost of the Diagnostic Tests was taken from
the 2002 scale of the Physicians Medical College of
Barcelona. Cost of the medication used: the MSP accord-
ing to the cheapest prices published in the 2002 Pharma-
ceutical Ofﬁcial Book. RESULTS: (In brackets means per
patient or episode). Total Days of Hospitalization: 1,911
(7.77), Total Cost of Hospitalization or Hotel Cost:
€435,937.32 (1,772.10), Total Cost of Diagnosis Tests:
€23,284.93 (94.65), Total Cost of Oxygen-therapy and
other treatments: €3,646.36 (14.82), Total Sum Cost 
of Hospital Pharmacological Treatment: €24,644.79
(100.18), Total Sum Cost of Continuing Therapy after
discharge: €7,071.79 (28.75). The ﬁnal Total Cost was
€494,585.19, with an Average Cost per patient or episode
of €2,010.51, and an Average Daily Cost per patient of
€258.75. CONCLUSIONS: Total cost of COPD exacer-
bation is mainly determined by the hospital costs (88.1%
of the ﬁnal cost) and, secondarily, by the hospital 
pharmacological treatment cost (5.0%) and by the 
diagnosis tests cost (4.7%).
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AN ANALYSIS OF THE LENGTH AND COSTS OF
RESPIRATOR USE WITH OBSERVATIONAL DATA
BASED ON MEDICAL RECORDS
Watanabe R1, Ohkusa Y2
1Kyoto University, Kyoto, Japan; 2Osaka University, Ibaragi,
Osaka, Japan
OBJECTIVES: This research documents an analysis of
the impact of respirator use on medical expenses with
observational data based on medical records from all 
over Japan. METHODS: The data set included records
of medical procudures during a single month, but not 
for procedures and information extending over plural
months. Accordingly, censoring was an important
problem. To overcome this, samples were classiﬁed into
four groups; complete, right censoring, left censoring and
both censoring ones using length of respirator use and
hospital stay. Then, the Gompertz model was applied to
calculate the expected length of respirator use. For cal-
culation of estimates, bootstrappings technique was used.
Simultaneously, medical expenses for respirator use were
also estimated. RESULTS: The estimated length of 
respirator use was from 10 to 104 days, with expected
medical expenses per case of from 30,000 to 40,000 yen
and the number of respirator usages on aggregate of
5510. CONCLUSIONS: This means the impact of respi-
rator use on medical expenses of Japan is from 18 to 250
billion yen per year.
